Literature DB >> 16095456

Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study.

S Duru1, U Koca, S Oztekin, C Olguner, A Kar, C Coker, C Ulukuş, C Taşcł, Z Elar.   

Abstract

BACKGROUND: Anti-inflammatory action of Antithrombin III (AT III) is still not well understood in ischemia/reperfusion (I/R) injury. In the present study, we aimed to investigate the anti-inflammatory action of AT III on remote lung and local skeletal muscle tissue injury in a rat model of bilateral lower limb I/R model.
METHODS: Bilateral lower limb ischemia and reperfusion were produced by means of tourniquets occlusions and releases, respectively. Three groups of rats were used in this controlled study: sham group (sham, n=3) underwent 5 h of anesthesia only; control group (I/R, n=7) underwent 3 h of bilateral lower limb ischemia followed by 2 h of reperfusion; and AT III pretreated group (I/R-AT III, n=6) underwent the same procedure as the control group, but also received i.v. 250 U kg-1 AT III 30 min before ischemia induction under midazolam and fentanyl anesthesia. MEASUREMENTS AND
RESULTS: Lung and muscle tissue accumulation of polymorphonuclear leukocytes (PMN) were assessed by measuring tissue myeloperoxidase (MPO) activity. Histopathological changes in tissues were assessed by PMN counts in the lung, and muscle tissues and by histological lung injury score. Plasma 6-keto prostaglandin F(1alpha) and tumor necrosis factor alpha levels were measured by an enzyme immunoassay technique. Myeloperoxidase activity could not be detected in the muscle tissues of all groups. The lung and muscle tissue PMN counts in the I/R group were significantly higher compared with the I/R-AT III group (P<0.05).
CONCLUSIONS: Data from the present study provides some evidence that AT III pretreatment attenuates remote lung and local skeletal muscle tissue injury caused by lower limb I/R.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16095456     DOI: 10.1111/j.1399-6576.2005.00764.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  The effect of Antithrombin-III on routine hematological and biochemical parameters in an experimental animal model of skeletal muscle ischemia-reperfusion injury.

Authors:  Dg Karamanos; Cd Karkos; Ag Kambaroudis; M Kritsepi; S Papadopoulos; Ct Spyridis; Ts Gerassimidis
Journal:  Hippokratia       Date:  2014 Jul-Sep       Impact factor: 0.471

2.  Serpin induced antiviral activity of prostaglandin synthetase-2 against HIV-1 replication.

Authors:  James B Whitney; Mohammed Asmal; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

3.  Proteomics Analysis to Identify and Characterize the Biomarkers and Physical Activities of Non-Frail and Frail Older Adults.

Authors:  Ching-Hung Lin; Chen-Chung Liao; Chi-Huang Huang; Yu-Tang Tung; Huan-Cheng Chang; Mei-Chich Hsu; Chi-Chang Huang
Journal:  Int J Med Sci       Date:  2017-02-23       Impact factor: 3.738

4.  The effects of amantadine on lung tissue in lower limb ischemia/reperfusion injury model in rats.

Authors:  Mustafa Orhan; Ayça Taş Tuna; Yusuf Ünal; Mustafa Arslan; Hayrullah Yazar; Şaban Cem Sezen; Sezen Irmak Gözükara; Onur Palabıyık
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-01-13       Impact factor: 0.332

5.  Effect of picroside II on erythrocyte deformability and lipid peroxidation in rats subjected to hind limb ischemia reperfusion injury.

Authors:  Faruk Metin Çomu; Yiğit Kılıç; Abdullah Özer; Mehmet Kirişçi; Ali Doğan Dursun; Tolga Tatar; Mustafa Hakan Zor; Hakan Kartal; Ayşegül Küçük; Hakan Boyunağa; Mustafa Arslan
Journal:  Drug Des Devel Ther       Date:  2016-03-01       Impact factor: 4.162

6.  Effect of picroside II on hind limb ischemia reperfusion injury in rats.

Authors:  Yiğit Kılıç; Abdullah Özer; Tolga Tatar; Mustafa Hakan Zor; Mehmet Kirişçi; Hakan Kartal; Ali Doğan Dursun; Deniz Billur; Mustafa Arslan; Ayşegül Küçük
Journal:  Drug Des Devel Ther       Date:  2017-06-26       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.